SOURCE: Aradigm

April 17, 2007 04:00 ET

Aradigm Announces Scientific Advisory Board Completion and Meeting

HAYWARD, CA -- (MARKET WIRE) -- April 17, 2007 --Aradigm Corporation (OTCBB: ARDM) today announced the completion of the appointments to its new Scientific Advisory Board ("SAB").

In accordance with its changed strategic direction and product focus in the area of severe respiratory disease treatments, Aradigm has undertaken a redesign of its SAB. The Company has now completed this task and the SAB has the following members whose expertise lies in the core areas of Aradigm's business:

Peter R. Byron, Ph.D. - Medical College of Virginia, Virginia Commonwealth
University
(Aerosol Science/Pharmaceutics)

Peter S. Creticos, M.D. - The Johns Hopkins University School of Medicine
(Allergy/Immunology/Asthma)

Stephen J. Farr, Ph.D. - Zogenix, Inc.
(Pulmonary Delivery/Pharmaceutics)

Phyllis Gardner, M.D. - Stanford University
(Clinical Pharmacology/Drug Development/Cystic Fibrosis)

Michael Konstan, M.D. - Rainbow Babies and Children's Hospital
(Pulmonary Disease/Cystic Fibrosis)

Michael Powell, Ph.D. - Sofinnova Ventures
(Drug Development/Severe pulmonary disease opportunities)

Robert E. Ratner, M.D. - MedStar Research Institute
(Endocrinology/Diabetes)

Adam Wanner, M.D. - University of Miami
(Pulmonary Disease/Chronic Obstructive Pulmonary Disease)

Martin Wasserman, Ph.D. - Roche, AtheroGenics (retired)
(Asthma and other respiratory disease/Preclinical Development)
"This reconstituted SAB has now met for the first time, and, along with the input of several consultants, has already provided very helpful guidance into the clinical development plan for our lead product candidates," said Dr. Tunde Otulana, Aradigm's Senior Vice President and Chief Medical Officer. "They have also provided several very promising new product candidate ideas within severe respiratory disease, which Aradigm will be investigating in the coming months. I am delighted that we have succeeded in putting together an outstanding advisory board, consisting of such renowned experts in respiratory medicine, pulmonary pharmacology, and inhalation drug delivery."

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense.

More information about Aradigm can be found at www.aradigm.com.

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and AERx are registered trademarks of Aradigm.